4-(2-吡啶-2-基乙氧基)苯胺双盐酸盐 | 344561-49-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-吡啶-2-基乙氧基)苯胺双盐酸盐
• 英文名称: 4-[2-(2-pyridinyl)ethoxy]phenylamine
• 英文别名: 4-(2-Pyridin-2-ylethoxy)aniline
• CAS: 344561-49-5
• 化学式: C₁₃H₁₄N₂O
• mdl: MFCD04971000
• 分子量: 214.267
• InChiKey: JJNGKTZBDIIYMV-UHFFFAOYSA-N

物化性质

• 沸点：
  398.1±27.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(2-吡啶-2-基乙氧基)苯胺双盐酸盐 在 copper(I) oxide 、 盐酸 、 sodium nitrite 作用下， 反应 18.5h， 生成 5-[4-[2-(2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
  参考文献：
  名称：

  Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.

  摘要：

  合成了100多种5-取代的噻唑烷-2,4-二酮类化合物，并通过遗传性肥胖和糖尿病小鼠（KK黄色小鼠）评估了它们的降血糖和降血脂活性。结构-活性关系研究表明，5-(4-羟基苄基)部分对于显著活性是必要的。在这些化合物中，5-(4-环己基甲氧基)苄基噻唑烷-2,4-二酮（47）、5-[4-(1-甲基环己基甲氧基)苄基]-噻唑烷-2,4-二酮（49，ADD-3878）和5-{4-[2-(3-吡啶基)乙氧基]苄基}噻唑烷-2,4-二酮（59）在活性和毒性方面表现出最佳特性。

  DOI：

  10.1248/cpb.30.3580
• 作为产物：
  描述：

  4-<2-(2-pyridyl)ethoxy>nitrobenzene 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 4-(2-吡啶-2-基乙氧基)苯胺双盐酸盐
  参考文献：
  名称：

  Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.

  摘要：

  合成了100多种5-取代的噻唑烷-2,4-二酮类化合物，并通过遗传性肥胖和糖尿病小鼠（KK黄色小鼠）评估了它们的降血糖和降血脂活性。结构-活性关系研究表明，5-(4-羟基苄基)部分对于显著活性是必要的。在这些化合物中，5-(4-环己基甲氧基)苄基噻唑烷-2,4-二酮（47）、5-[4-(1-甲基环己基甲氧基)苄基]-噻唑烷-2,4-二酮（49，ADD-3878）和5-{4-[2-(3-吡啶基)乙氧基]苄基}噻唑烷-2,4-二酮（59）在活性和毒性方面表现出最佳特性。

  DOI：

  10.1248/cpb.30.3580

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20090041786A1

  公开（公告）日：2009-02-12

  The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

  这项发明涵盖了具有I-V公式的化合物以及使用这些化合物在治疗需要调节JAK通路或抑制JAK激酶，特别是JAK3的情况下可能具有治疗作用的组合物和方法。
• Amide compounds
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040133008A1

  公开（公告）日：2004-07-08

  A compound of the formula (I) 1 wherein R 1 is hydrogen, lower alkyl, lower alkenyl, halo(lower)alkyl, cyclo(lower)alkyl, lower alkoxy, lower alkylthio, acyl, optionally substituted aryl or NR 3 R 4 ; R 2 is hydrogen; or aryl or heteroaryl, each of which may be substituted; X is direct bond or bivalent residue derived from piperazine; Y is -(A 1 ) n -(A 2 ) m -, wherein n and m are independently 0 or 1); 2 is bivalent residue derived from arene or heteroarene; and 3 is bivalent residue derived from arene or heteroarene, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  化合物的式子为（I）1，其中R1为氢、低级烷基、低级烯基、卤素（低）烷基、环（低）烷基、低级烷氧基、低级烷硫基、酰基、可选取代的芳基或NR3R4；R2为氢；或芳基或杂环芳基，每个可以被取代；X为直接键或由哌嗪衍生的二价残基；Y为-(A1)n-(A2)m-，其中n和m独立地为0或1）；2为由芳烃或杂芳烃衍生的二价残基；3为由芳烃或杂芳烃衍生的二价残基，或其盐。本发明的化合物及其盐抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由高循环Apo B水平引起的疾病或状况的药物。
• Heterocyclic amide compounds as apolipoprotein b inhibitors
  申请人：Takasugi Hisashi

  公开号：US20050038035A1

  公开（公告）日：2005-02-17

  The present invention relates to a compound of the formula (I) wherein R 1 is optionally substituted aryl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A 1 ) m1 -(A 2 ) m2 -; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及一种化合物，其分子式为（I），其中R1为可选取代芳基；R2为可选取代芳基、可选取代杂环芳基、可选取代较低环烷基、可选取代芳氧基、可选取代芳基磺酰基、乙烯基、氨基甲酰基、保护羧基或保护氨基；环A为由可选取代芳基或可选取代杂环芳基衍生的二价残基；X为由环烷烯、萘、不饱和的5或6元杂单环基衍生的二价残基，每种残基均可选取代，以及取代苯基；Y为-(A1)m1-(A2)m2-；Z为直接键或哌嗪，或其盐。本发明的化合物及其盐能抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于高循环Apo B水平引起的疾病或病症的药物。
• Compositions and methods for inhibition of the jak pathway
  申请人：Li Hui

  公开号：US20060293311A1

  公开（公告）日：2006-12-28

  The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

  本发明涵盖具有I-V式的化合物，以及使用这些化合物在调节JAK通路或抑制JAK激酶，特别是JAK3，在治疗可能有治疗用途的疾病中的组合物和方法。
• AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS
  申请人：Hamlyn Richard

  公开号：US20100204224A1

  公开（公告）日：2010-08-12

  Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents; wherein (1) represents (A), (B) or (C); R 1 represents: (a) -L-A or L′-A′ wherein L represents a bond or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, A represents a phenyl, 5- to 10-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 10 membered heterocyclyl group, L′ represents a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, and A′ represents -Het-A or —X-A wherein Het represents —O—, —S— or NR′, and X represents —CO—, —SO—, SO 2 —, —CO—O—, CO—S, CONR′, —O—CO—, —S—CO— or NR′—CO—, wherein R′ represents hydrogen or C 1 -C 6 alkyl; (b) -L-A-A′ or -L-A-L-A wherein A′ is as defined above, each A is the same or different and is as defined above and each L is the same or different and is as defined above; (c) -A-Z-A wherein Z is -Het-L′, —X-L′, -L′-Het- or L′-X, wherein Het, L′ and X are as defined above and each A is the same or different and is as defined above; (d) -A-Het-Y or -A-X—Y wherein is [L′-Het] n -L′, [L′-Het] n -L′, -[L′-Het] n -A, -L′-B-L′, -L′-B-A or -A-L-A wherein n is from 1 to 4 and B is —X—, —NR′—CO—NR′, —O—CO—NR′— or —NR′—CO—O, and wherein X and L are as defined above, each A is the same or different and is as defined above, each L′ is the same or different and is as defined above, each R′ is the same or different and is as defined above and each Het is the same or different and is as defined above; or (e) -L-CR(A)(A′) or L-CR(A)(L-A) wherein R is hydrogen or C 1 -C 4 alkyl, A′ is as defined above, each L is the same or different and is as defined above and each A is the same or different and is as defined above; R 2 represents -L-A-, L′-A′, -L-A-A′ or L-A-L-A wherein L′ and A′ are as defined above, each L is the same or different and is as defined above and each A is the same or different and is as defined above J represents —NR 3 —, —O— or a direct bond wherein R 3 represent s hydrogen C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; p is an integer from 1 to 3; q is 1 or 2; and one of E and E′ is —CH 2 — and the other is a direct bond.

  式(I)的化合物及其药学上可接受的盐被发现是SNS钠通道的拮抗剂。它们因此可作为镇痛和神经保护剂使用；其中(1)代表(A)、(B)或(C)；R1代表：(a) -L-A或L'-A'，其中L代表一个键或一个C1-C6烷基，C2-C6烯基或C2-C6炔基基团，A代表一个苯基，5-至10-成员杂芳基，C3-C6环烷基或5-至10-成员杂环基团，L'代表一个C1-C6烷基，C2-C6烯基或C2-C6炔基基团，A'代表-Het-A或-X-A，其中Het代表-O-、-S-或NR'，X代表-CO-、-SO-、SO2-、-CO-O-、CO-S、CONR'、-O-CO-、-S-CO-或NR'-CO-，其中R'代表氢或C1-C6烷基；(b) -L-A-A'或-L-A-L-A，其中A'如上所定义，每个A相同或不同，如上所定义，每个L相同或不同，如上所定义；(c) -A-Z-A，其中Z为-Het-L'、-X-L'、-L'-Het-或L'-X，其中Het、L'和X如上所定义，每个A相同或不同，如上所定义；(d) -A-Het-Y或-A-X-Y，其中是[L'-Het]n-L'、[L'-Het]n-L'、-[L'-Het]n-A、-L'-B-L'、-L'-B-A或-A-L-A，其中n为1至4，B为-X-、-NR'-CO-NR'-、-O-CO-NR'-或-NR'-CO-O，其中X和L如上所定义，每个A相同或不同，如上所定义，每个L'相同或不同，如上所定义，每个R'相同或不同，如上所定义，每个Het相同或不同，如上所定义；或(e) -L-CR(A)(A')或L-CR(A)(L-A)，其中R为氢或C1-C4烷基，A'如上所定义，每个L相同或不同，如上所定义，每个A相同或不同，如上所定义；R2代表-L-A-、L'-A'、-L-A-A'或L-A-L-A，其中L'和A'如上所定义，每个L相同或不同，如上所定义，每个A相同或不同，如上所定义；J代表-NR3-、-O-或直接键，其中R3代表氢、C1-C6烷基、C2-C6烯基或C2-C6炔基；p为1至3的整数；q为1或2；E和E'中的一个为-CH2-，另一个为直接键。